Why the Cann (ASX:CAN) share price is pushing higher

The Cann Group Ltd (ASX:CAN) share price is pushing higher today following a couple of announcements. Here's what you need to know…

| More on:
A fit man flexes his muscles, indicating a positive share price movement on the ASX market

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cann Group Ltd (ASX: CAN) share price is pushing higher today following the release of a couple of announcements.

At the time of writing, the cannabis company's shares are up 2.5% to 79 cents.

Why is the Cann share price pushing higher?

Investors have been buying Cann shares today after it announced a new acquisition.

According to the release, the company has agreed to acquire the Satipharm business from Harvest One Cannabis in an all-scrip deal. The two parties have agreed a total maximum consideration of C$4 million worth of Cann shares, including conditional deferred consideration of up to C$1.5 million.

Satipharm is a Europe-based business exclusively licensed to develop and market the proprietary Gelpell delivery system for cannabinoids.

Gelpell capsules are manufactured by Swiss-based GMP manufacturer Gelpell AG which, with Satipharm, jointly owns the patented delivery technology. The release explains that Satipharm has generated data in support of its claims that this patented delivery technology exhibits improved stability and bioavailability of cannabinoids compared to other formulations.

It currently has existing distribution agreements in place in the UK, Ireland, and Eastern Europe.

Cann's CEO, Peter Crock, commented: "The technology will allow us to develop more targeted and effective dosage forms of both low dose CBD and differentiated THC prescription formulations of medicinal cannabis. We believe the Satipharm product offers superior efficacy, delivery and stability qualities compared to other products and we expect these unique features, coupled with its presentation in a more familiar capsule form expected of pharmaceuticals, to generate greater confidence from prescribing doctors."

"The Satipharm acquisition provides an opportunity to accelerate both short-term and longer-term revenues. Over time, we believe we can expand the number of markets into which these products are sold and expand the range of formulations to be targeted at both the OTC and prescription segments," said Mr Crock.

Speaking of revenues, Cann also provided a revenue update this morning.

How is Cann performing?

Unfortunately, this announcement wasn't as positive as the acquisition announcement. It turns out that Cann isn't performing as well as it was expecting.

According to the release, due to COVID-19 related regulatory delays, management has downgraded its revenue guidance materially.

Cann is now forecasting revenues of between $8 million and $10 million in FY 2021. This is down 33% to 46.5% from its previous guidance of $15 million. It also remains subject to relevant regulatory clearances being secured.

Management notes that substantial delays have been incurred in relation to obtaining required regulatory approvals both in Australia and in Germany.

But judging by the Cann share price performance today, the acquisition news appears to have been enough to offset its revenue guidance downgrade.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Fallers

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why Healius, Opthea, Peninsula Energy, and Wildcat shares are falling today

These shares are having a tough finish to the week. But why?

Read more »

A worried man holds his head and look at his computer.
Share Fallers

Why Graincorp, Light & Wonder, Orica, and Wildcat shares are falling today

These shares are having a tough time on Thursday. But why?

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward representing the ASX tech share sell-off today
Share Fallers

Why Insignia, Light & Wonder, Mineral Resources, and Nuix shares are sinking today

These shares are having a difficult time on hump day. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Endeavour, Global Data Centre, OFX, and Paladin Energy shares are dropping today

Why are these shares under pressure today? Let's find out.

Read more »

A man sits wide-eyed at a desk with a laptop open and holds one hand to his forehead with an extremely worried look on his face as he reads news of the Bitcoin price falling today on his mobile phone
Share Fallers

ASX 200 uranium stock alert: Paladin Energy shares just crashed 29%!

Paladin Energy shares are under intense selling pressure on Tuesday.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why Champion Iron, Endeavour, Infomedia, and Resolute Mining shares are sinking today

These shares are starting the week in the red. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Arcadium Lithium, Block, Jumbo, and Mineral Resources shares

These shares are ending the week in the red. Why are investors selling them?

Read more »